• $2,690.00
    Market Cap
  • -99.00%
    1-Year Change
  • Drug Manufacturers - Specialty & Generic
    Industry
Annual
Quarterly
12/31/2023
12/31/2022
12/31/2021
Income Statement
Total Operating Revenue
60,453
+443.01%
11,133
+100.74%
5,546
N/A
Cost of Revenue
85,610
+1,040.40%
7,507
-97.14%
262,620
N/A
Gross Profit
-25,157
-793.79%
3,626
+101.41%
-257,074
N/A
Sales and Marketing Expense
N/A
N/A
N/A
N/A
N/A
N/A
Research and Development Expense
N/A
N/A
N/A
N/A
N/A
N/A
Depreciation and Amortization Expense
82,472
+0.48%
82,076
-51.01%
167,536
N/A
Total Operating Expenses
1.2M
+46.67%
794,987
-61.37%
2.1M
N/A
Operating Profit
-1.2M
-250.52%
791,361
+134.18%
-2.3M
N/A
Interest Income
N/A
N/A
N/A
N/A
N/A
N/A
Interest Expense
-55,176
+69.74%
-32,507
-1.61%
-33,040
N/A
Interest Income and Expense and Net
-55,176
+69.74%
-32,507
-1.61%
-33,040
N/A
Total Nonoperating Income and Expense
-141,197
+23.23%
-114,583
-76.17%
-480,833
N/A
Income before Taxes
-1.2M
-250.52%
791,361
+134.18%
-2.3M
N/A
Income Taxes
N/A
N/A
N/A
N/A
N/A
N/A
Extraordinary Items
N/A
N/A
N/A
N/A
385,989
N/A
Net Income
1.3M
+47.07%
905,944
+132.40%
-2.8M
N/A
Net Income from Continuing Operations Applicable to Common
-1.3M
+47.07%
-905,944
-67.60%
-2.8M
N/A
Basic EPS and Net Income
0.00
N/A
0.00
N/A
N/A
N/A
Diluted EPS and Net Income
0.00
N/A
0.00
N/A
N/A
N/A
Basic Weighted Average Shares
2.7B
+0.37%
2.7B
+2.16%
2.6B
N/A
Diluted Weighted Average Shares
2.7B
+0.37%
2.7B
+2.16%
2.6B
N/A
Balance Sheet
Cash and Cash Equivalents
79,345
+2,688.93%
2,845
-98.56%
197,255
N/A
Short-Term Investments
N/A
N/A
N/A
N/A
N/A
N/A
Cash and Cash Equivalents and Short-Term Investments
79,345
+2,688.93%
2,845
-98.56%
197,255
N/A
Total Current Assets
79,345
+2,107.09%
3,595
-98.19%
198,153
N/A
Accumulated Depreciation
185,560
+80.00%
103,089
-73.40%
387,578
N/A
Property and Plant and Equipment and Net
1.1M
-7.12%
1.2M
-6.62%
1.2M
N/A
Total Long-Term Assets
1.1M
-7.12%
1.2M
-6.62%
1.2M
N/A
Total Assets
1.3M
+10.18%
1.2M
-19.23%
1.4M
N/A
Income Taxes Payable
17,332
-93.75%
277,226
+96.70%
140,935
N/A
Total Short-Term Debt
515,672
+62.16%
318,003
-6.70%
340,855
N/A
Total Current Liabilities
2.5M
+40.03%
1.8M
+37.42%
1.3M
N/A
Total Long-Term Debt
515,826
+310.59%
125,629
-57.72%
297,102
N/A
Total Long-Term Liabilities
78,718
-68.67%
251,258
-15.43%
297,102
N/A
Total Liabilities
2.6M
+34.95%
1.9M
+32.01%
1.5M
N/A
Retained Earnings
-13.9M
+10.60%
-12.6M
+7.76%
-11.7M
N/A
Total Stockholders Equity
-1.3M
+73.17%
-752,895
+6,199.85%
-11,951
N/A
Total Shares Outstanding
2.7B
0.00%
2.7B
+0.49%
2.7B
N/A
Cash Flow
Cash from Operating Activities
-137,801
-74.07%
-531,488
-38.60%
-865,664
N/A
Capital Expenditures
N/A
N/A
N/A
N/A
147,999
N/A
Cash from Investing Activities
-125,000
N/A
N/A
N/A
-147,999
N/A
Dividends Paid
N/A
N/A
N/A
N/A
N/A
N/A
Cash from Financing Activities
339,301
+0.66%
337,078
-65.00%
963,026
N/A
Financials Ratio
Gross Margin
-41.61%
-227.77%
32.57%
N/A
N/A
N/A
Operating Margin
-1,970.38%
-127.72%
7,108.25%
N/A
N/A
N/A
Return on Assets
109.12%
+56.60%
69.68%
N/A
N/A
N/A
Return on Equity
-129.56%
-45.31%
-236.90%
N/A
N/A
N/A
Revenue Growth
443.01%
+339.76%
100.74%
N/A
N/A
N/A
Current Ratio
0.03
+1,485.00%
0.002
N/A
N/A
N/A
Cash Ratio
0.03
+1,881.25%
0.002
N/A
N/A
N/A
Debt-to-Equity Ratio
-0.79
+34.27%
-0.59
N/A
N/A
N/A
Debt-to-Assets Ratio
0.81
+111.05%
0.38
N/A
N/A
N/A

Earnings & Revenue History

Debt-to-Assets

Cash Flow